Vita Mojo Raises US$30 Million to Help Restaurant and Hospitality Chains in Europe Tackle the Digital Future
30.6.2022 13:00:00 EEST | Business Wire | Press release
Vita Mojo, the European leader in “front-of-house” restaurant software powering digital ordering and the management of smarter, more-efficient kitchen and delivery operations, has raised US$30 million in new financing to refine its product and expand into new markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005213/en/
Vita Mojo Co-Founders Nick Popovici (left) and Stefan Catoiu. (Photo: Business Wire)
The funding round was led by global technology investment firm Battery Ventures, an investor in a number of U.S.-based restaurant and hospitality-tech companies including Olo* and CrunchTime! Information Systems*. Battery General Partner Morad Elhafed and Principal Zak Ewen will join Vita Mojo’s board. Vita Mojo – which sells to restaurants, pubs, coffee shops, bakeries and fast-casual eateries – counts large chains among its customer base including Nando’s, GAIL’s Bakery, Le Pain Quotidien, LEON, JKS Group and Neat Burger.
“The headwinds and opportunities facing restaurants today are enormous. Operators are adapting to changing customer preferences around dining and ordering as well as monumental market disruptions – first the pandemic, then supply-chain disruptions and a labour shortage. This has dramatically changed how restaurants operate and shrunk profit margins for those not able to adapt,” said Vita Mojo CEO Nick Popovici, who originally founded the company as a healthy-restaurant chain and then pivoted to restaurant software.
Recent research from Vita Mojo shows over four-fifths (84%) of Generation Z and millennials (82%) would rather visit a restaurant with self-serve kiosks than a restaurant without. According to Popovici, “Digital transformation is essential for the hospitality sector today, and our technology helps companies move forward.”
Vita Mojo also announced new technology that empowers restaurant customers to make better food choices when dining out. A new, integrated feature in the company’s technology lets restaurants accurately and seamlessly display nutrition and allergen information across their menus by pulling the data directly from recipe-management software. A U.K.-wide survey conducted by Vita Mojo earlier this spring found that 43% of customers would be more likely to eat at a restaurant with calorie labelling on the menu.
Vita Mojo is based in London and serves over 130 operators across the U.K. and Europe. The company’s platform enables restaurants to manage their core operations in one integrated system, from digital ordering via their own channels and third-party delivery platforms – such as Just Eat, Deliveroo and Uber Eats – to smarter kitchen and back-of-house management. Unlike most hospitality tech providers who specialise in one element of the restaurant tech stack, Vita Mojo is a powerful, full-suite platform that brings together both customer ordering and kitchen operations.
For customers, Vita Mojo enables self-service ordering from kiosks and customers’ own devices, as well as a more-efficient takeaway experience. On the restaurant-management side, it empowers operators to seamlessly integrate all ordering channels into one system. Vita Mojo clients see an increase of 35% in average order value and an average reduction in labour costs of up to 40%.
“With the funding round complete, now is the time for action,” said Vita Mojo Co-founder and COO Stefan Catoiu. "This investment will accelerate our product roadmap, as well as help upgrade our data and insights features and grow our client success, product and engineering teams. We’re on track to double our headcount over the next year, with the majority of our recruitment focused on taking our client support to the next level.”
Restaurants now realise they can see a significant revenue boost from an integrated, multi-channel ordering system, given the rise in delivery and takeaway orders that has outlasted the pandemic. The vast amounts of data generated by Vita Mojo’s technology, from order to bill, helps restaurants serve customers better and build loyalty by personalising their experience and offering customised marketing based on previous order activity.
“Vita Mojo has a bold vision for the restaurant industry,” said Battery’s Morad Elhafed. “Offering one platform that combines digital ordering with kitchen operations is a valuable proposition that solves the headaches of managing multiple point solutions and systems. Our experience with restaurant tech in the U.S. makes us excited about Vita Mojo’s opportunity in Europe – and its overall mission of taking restaurants to the next level by simplifying their operations and delivering a remarkable experience for customers.”
*For a full list of all Battery investments and exits, click here .
About Vita Mojo
Vita Mojo is a software company revolutionising the hospitality industry. Founded in 2016 by Nick Popovici and Stefan Catoiu, Vita Mojo started life as the UK’s first cashless, cashier-less and digital-only restaurants. They used their experience to build and refine Vita Mojo’s full-suite technology platform which combines everything a restaurant operator needs to thrive: award-winning digital ordering, Point of Sale, delivery and order management, kitchen operations and marketing & growth tools. Today, more than 130 operators across 5 countries (including LEON, Nando’s, Le Pain Quotidien and GAIL’s Bakery) use Vita Mojo to grow sales, streamline their operations and create remarkable customer experiences.
About Battery Ventures
Battery partners with exceptional founders and management teams to developing category-defining businesses in markets including software and services, enterprise infrastructure, consumer technology, healthcare IT and industrial tech/life-sciences tools. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from offices in Boston, San Francisco, Menlo Park, London New York, and Tel Aviv. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220630005213/en/
Contact information
Media Contact:
Stephanie Gnibus
GMK Communications
stephanie@gmkcommunications.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
